We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Urinary Microbiome Linked to Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 May 2022

Prostate cancer is the most common non-skin malignancy in men in developed countries, with over 250,000 deaths annually worldwide. More...

The clinical course of prostate cancer is highly heterogeneous, and critical decisions are made about the likelihood of aggressive disease based on information obtained at presentation.

Determining urinary biomarkers to identify aggressive prostate cancer is an area of growing interest. Material secreted by the prostate gland appears in the urine, and reflux of urine into the prostate is well established, supporting the existence of a prostate-urine loop.

Urology Oncologists at the Norwich Medical School (Norwich, UK) used urine samples collected from 318 people in the UK who were being assessed for prostate cancer or for blood in their urine. They then examined the patients’ health outcomes for up to six years after the sample was taken. Urine sediments and extracellular vesicle fractions were prepared, with an additional step for the detection of bacteria by microscopy. Prostate secretions were collected via manual compression of the excised prostate less than 20 minutes after prostatectomy.

DNA was extracted from urine sediment with repeated bead-beating extraction to maximize bacterial DNA yield. Bacterial 16S DNA was amplified and sequenced (V1-V3/V3-V5 hypervariable regions). Quantitative polymerase chain reaction (qPCR) assays detected several bacterial genera and species. Urine extracellular vesicle total RNA was extracted from 40 urine samples and were sequenced.

Urine or prostate secretion samples were inoculated into pre-reduced PY broth or Brucella blood agar plates with 5% sheep blood and vitamin K1/hemin supplementation (Becton Dickinson GmbH, Heidelberg, Germany), and grown in an anaerobic cabinet. Pure colonies were picked and prepared for DNA extraction, and sequenced with Nextera XT library preparation on a MiSeq (Illumina, San Diego, CA, USA) using V3 reagents (2 × 300 bp). MinION nanopore sequencing (Oxford Nanopore Technologies, Oxford, UK) was used on three novel species for hybrid assembly (Unicycler).

The investigators demonstrated an association between the presence of bacteria in urine sediments and higher D’Amico risk prostate cancer. Characterization of the bacterial community led to the identification of four novel bacteria (Porphyromonas sp. nov., Varibaculum sp. nov., Peptoniphilus sp. nov., and Fenollaria sp. nov.) that were frequently found in patient urine, and a definition of a patient subgroup associated with metastasis development. The presence of five specific anaerobic genera, which includes three of the novel isolates, was associated with cancer risk group, in urine sediment, urine extracellular vesicles, and cancer tissue, with a meta-analysis hazard ratio for disease progression of 2.60.

Rachel Hurst, PhD, a Senior Research Associate and first author of the study, said, “We have identified a group of five bacterial genera linked with high-grade prostate cancer and more rapid progression to aggressive cancer.”

The authors concluded that their results established the importance of bacteria present in urine and the prostate as potential prognostic markers and, when considered together with data from other studies, provide a starting point for future investigations into the roles of bacteria in prostate cancer pathogenesis and evolution. The study was published on April 18, 2022 in the journal European Urology Oncology.

Related Links:
Norwich Medical School 
Becton Dickinson 
Illumina 
Oxford Nanopore Technologies 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.